Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2015.00005
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

EGFR and EGFRvIII in Glioblastoma: Partners in Crime

Cancer Cell
Cancer ResearchOncologyCell Biology
2013English

EGFR Cooperates With EGFRvIII to Recruit Macrophages in Glioblastoma

Cancer Research
Cancer ResearchOncology
2018English

Metabolic Targeting of EGFRvIII/PDK1 Axis in Temozolomide Resistant Glioblastoma

Oncotarget
Oncology
2017English

Biomarkers and Therapeutic Advances in Glioblastoma Multiforme

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2017English

EGFR and mTOR as Therapeutic Targets in Glioblastoma

Oncotarget
Oncology
2019English

EGFR, P53, IDH-1 and MDM2 Immunohistochemical Analysis in Glioblastoma: Therapeutic and Prognostic Correlation

Arquivos de Neuro-Psiquiatria
Biological PsychiatryNeurology
2015English

Near-Infrared Photoimmunotherapy Targeting EGFR - Shedding New Light on Glioblastoma Treatment

International Journal of Cancer
Cancer ResearchOncology
2018English

Lessons Learned From Rindopepimut Treatment in Patients With EGFRvIII-expressing Glioblastoma

Translational Cancer Research
Cancer ResearchOncologyRadiologyNuclear MedicineImaging
2018English

Forced Dimerization Increases the Activity of EGFR/EGFRvIII and Enhances Its Oncogenicity

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy